The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenues | 78 | 947 | 1,850 | - |
| Research and development-Legacy Selecta Programs | - | 0 | 0 | - |
| Research and development-Descartes08For MG | 12,135 | 5,391 | 17,502 | - |
| Research and development-Descartes08For Dermatomyositis | 227 | - | - | - |
| Research and development-Early Stage Programs | 355 | 1,567 | 4,228 | - |
| Research and development-Research And Development Employee Expenses | 3,828 | 4,899 | 11,927 | - |
| Research and development-Research And Development Share Based Payment Arrangement Expense | 949 | 682 | 4,090 | - |
| Research and development-Research And Development Facilities And Other Expenses | 1,969 | 2,150 | 5,598 | - |
| General and administrative | 7,114 | 8,197 | 23,271 | - |
| Impairment of indefinite-lived intangible and long-lived assets | - | 56,700 | - | - |
| Other expense (income), net | - | - | 27,040 | - |
| Other (income) expense, net | - | 13,103 | - | - |
| Other expense (income), net | -12,683 | - | - | - |
| Loss on disposal of property and equipment | - | 0 | 0 | 0 |
| Net loss | -39,182 | -92,576 | -35,902 | -1,824 |
| Forward contract liabilities revaluation | - | - | - | 0 |
| Depreciation and amortization | 615 | 608 | 606 | 1,745 |
| Impairment of indefinite-lived intangible and long-lived assets | - | 56,700 | - | - |
| Noncash lease expense | 235 | 215 | 192 | 371 |
| Stockbased compensation expense | 2,423 | 2,144 | 2,590 | 5,787 |
| Gain on change in warrant liability | -94 | -707 | -516 | -2,472 |
| Unbilled receivable | - | 0 | 0 | 0 |
| Loss (gain) on change in fair value of cvr liability | 13,800 | 23,100 | 16,900 | -35,646 |
| Loss on change in fair value of forward contract liabilities | - | 0 | 0 | - |
| Loss on impairment of investment | - | 2,000 | - | - |
| (benefit) provision for deferred taxes | - | -9,193 | - | - |
| Accounts receivable | -854 | 393 | 368 | -518 |
| Prepaid expenses and other assets | 246 | -264 | 438 | 5,124 |
| Accounts payable | 310 | -933 | 1,768 | 231 |
| Deferred revenue | - | 0 | 0 | 0 |
| Accrued expenses and other liabilities | -850 | 1,059 | -432 | -4,215 |
| Net cash used in operating activities | -22,135 | -17,712 | -15,600 | -40,629 |
| Purchases of property and equipment | 27 | 492 | 1,292 | 3,670 |
| Proceeds from the sale of property and equipment | - | 0 | - | - |
| Net cash used in investing activities | -27 | -492 | -1,292 | -3,670 |
| Proceeds from exercise of common warrants | - | 0 | 0 | 0 |
| Proceeds from issuance of series a preferred stock, gross in private placement | - | 0 | 0 | 0 |
| Net proceeds from issuance of common stock and series b preferred stock in private placement | - | 0 | 0 | - |
| Equity offering costs | 0 | 102 | 43 | 479 |
| Proceeds from exercise of stock options | 279 | 50 | 5 | 268 |
| Proceeds from at the market offering, net of commissions and expenses | 15,392 | - | - | - |
| Distribution of contingent value rights | 0 | 0 | 0 | 7,754 |
| Net cash provided by (used in) financing activities | 15,671 | -52 | -38 | -7,965 |
| Effect of exchange rate changes on cash | -7 | 11 | -10 | 44 |
| Net change in cash, cash equivalents, and restricted cash | -6,498 | -18,245 | -16,940 | -52,220 |
| Cash, cash equivalents and restricted cash at beginning of period | 126,874 | 145,119 | 214,279 | - |
| Cash, cash equivalents and restricted cash at end of period | 120,376 | 126,874 | 145,119 | - |
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)